Mirati Therapeutics, Inc.® presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in patients with non-small cell lung cancer harboring a KRASG12C mutation.
Mirati Therapeutics, Inc.® presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in patients with non-small cell lung cancer harboring a KRASG12C mutation.